Alnylam and peptidream enter into collaboration agreement to discover and develop peptide-sirna conjugates for targeted delivery of rnai therapeutics to a broader range of extrahepatic tissues

Cambridge, mass. & kawasaki city, kanagawa prefecture, japan--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, and peptidream, inc. (tokyo stock exchange: 4587), the leading peptide-based drug discovery company with its proprietary peptide discovery platform system (pdps), announced today a license and collaboration agreement to discover and develop peptide-sirna conjugates to create multiple opportunities to deliver rnai therapeutics to tiss
ALNY Ratings Summary
ALNY Quant Ranking